BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...and EVP and Chief Human Resources Officer Dawn Rogers. In other management news, vascular company Vasomune Therapeutics Inc....
BioCentury | Oct 17, 2017
Distillery Therapeutics

Ophthalmic disease

...Tie2 activator antibody, in preclinical testing to treat age-related macular degeneration (AMD) and diabetic retinopathy. Vasomune Therapeutics Inc....
BioCentury | Oct 27, 2014
Emerging Company Profile

Vasomune: Lassoing Tie2

...needed to activate the receptor is a job too big for small molecules or antibodies. Vasomune Therapeutics Inc....
...development. Companies and Institutions Mentioned MaRS Innovation , Toronto, Ontario Sunnybrook Research Institute, Toronto, Ontario Vasomune Therapeutics Inc....
...vascular leakage and reduces mortality in murine abdominal sepsis." Critical Care 15 R261 (2011) Sidebars Vasomune Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Oct 9, 2018
Company News

Management tracks: Pfizer unveils Bourla’s team

...and EVP and Chief Human Resources Officer Dawn Rogers. In other management news, vascular company Vasomune Therapeutics Inc....
BioCentury | Oct 17, 2017
Distillery Therapeutics

Ophthalmic disease

...Tie2 activator antibody, in preclinical testing to treat age-related macular degeneration (AMD) and diabetic retinopathy. Vasomune Therapeutics Inc....
BioCentury | Oct 27, 2014
Emerging Company Profile

Vasomune: Lassoing Tie2

...needed to activate the receptor is a job too big for small molecules or antibodies. Vasomune Therapeutics Inc....
...development. Companies and Institutions Mentioned MaRS Innovation , Toronto, Ontario Sunnybrook Research Institute, Toronto, Ontario Vasomune Therapeutics Inc....
...vascular leakage and reduces mortality in murine abdominal sepsis." Critical Care 15 R261 (2011) Sidebars Vasomune Therapeutics Inc....
Items per page:
1 - 3 of 3